Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS: GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes
NCT06919354Phase 1Recruiting
- Sponsor
- GentiBio
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GNTI-122 in type 1 diabetes mellitus (T1D) (3 cohorts), sponsored by GentiBio. Primary endpoint: Safety and tolerability of GNTI-122 at 78 weeks. Started Sep 2025; status: recruiting.
02
Drugs
GNTI-122
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06919354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919354.